Are Allergy Drops Safe? What the Evidence Actually Shows

Yes, allergy drops are generally considered safe enough for at-home use after the first dose, which is often supervised. The reasoning is rooted in the safety data: because the allergen is held under the tongue rather than injected, most reactions are mild and local, and systemic reactions are uncommon, affecting fewer than 0.1 percent of patients in our program. The most severe reaction, anaphylaxis, is estimated near 1 per 100 million doses, and no SLIT fatality has been reported worldwide. This low risk is precisely why regulators permit ongoing doses to be taken at home for FDA-approved sublingual tablets, and the same model is applied to drops. Sensible safeguards remain part of good care, including a supervised first dose and, in some cases, a prescribed epinephrine auto-injector. Your provider will explain exactly how your program handles the first dose and home dosing.

The main difference is the route of delivery. Allergy shots inject the allergen into tissue, where it can occasionally trigger a whole-body immune response, whereas allergy drops keep the allergen in contact with the oral lining, which tends to confine reactions to the mouth and throat. The evidence reflects this: allergy drops carry a lower risk of systemic reactions than shots, with systemic reactions affecting fewer than 0.1 percent of patients in our program and no SLIT fatality reported worldwide. It is important to frame this as a difference in risk profile rather than a blanket statement that drops are better, because shots have a strong, long-established evidence base and may be preferred in certain situations. Both are legitimate, effective options, and the right choice depends on your triggers, lifestyle, and medical history in consultation with your provider.

Allergy drops are compounded at a specialty pharmacy for each patient. The FDA does not review compounded products for safety or efficacy. The only FDA-approved sublingual immunotherapy products are tablets, such as Grastek, Ragwitek, and Odactra, which are single-allergen products. The compounded status of liquid drops reflects the regulatory difficulty of submitting drug applications for compounded, multi-allergen formulations rather than a specific safety problem. The safety evidence for sublingual immunotherapy, including the favorable local-versus-systemic profile and the absence of reported fatalities, draws on a broad clinical literature accumulated over decades, much of it from Europe where drops are widely used. Understanding the regulatory status helps set expectations, but it should not be confused with a finding that drops are unsafe. As with any treatment, talk with your provider about what the compounded status means for your situation.

Yes. Allergy drops are not appropriate for everyone, and certain conditions are contraindications. Uncontrolled or severe asthma is among the most important, because poorly controlled airways raise the stakes if a systemic reaction occurs, so asthma should be well controlled before starting. Eosinophilic esophagitis is another contraindication, given the association between this esophageal condition and the sublingual or swallowed allergen route. People with some cardiovascular conditions or on specific medications may also need individualized review. This is why a provider evaluates your full medical history and current medications before recommending treatment, and why the first dose is often supervised. If any of these apply to you, discuss them openly so your provider can tailor the plan, recommend an alternative, or take extra precautions appropriate to your circumstances.

A dangerous reaction to allergy drops is possible but very uncommon. The reassuring data show systemic reactions in fewer than 0.1 percent of patients in our program, most of them mild, and anaphylaxis estimated near 1 per 100 million doses, with no SLIT fatality reported worldwide. So while serious reactions can happen in theory, they are exceptionally rare in practice. The red flags to watch for are symptoms that move beyond the mouth: widespread hives, wheezing or shortness of breath, throat swelling that affects breathing, or feeling faint. If those occur, stop the drops, use a prescribed epinephrine auto-injector if the reaction is severe, and call 911. For everyday mild local effects such as an itchy mouth, no emergency action is needed. Keeping an emergency plan and an auto-injector available during the early weeks is a sensible precaution even though the overall risk is low.